Physician profile
Heather Cooper
NPI 1851054142
$2,305.25
in general payments reported to CMS, 2019-2025
25 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.38 · 2022: $349 · 2023: $431 · 2024: $1,175 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,782 · Consulting Fee: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,782.18 |
| Consulting Fee | $162.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $470.53 | 2024-2025 | |
| Lundbeck LLC | $337.63 | 2022-2024 | Vyepti |
| Alexion Pharmaceuticals, INC. | $238.04 | 2022-2024 | Ultomiris |
| Averitas Pharma INC. | $139.09 | 2023-2025 | Qutenza |
| Lilly USA, LLC | $137.93 | 2024 | Omvoh |
| Horizon Therapeutics Plc | $124.50 | 2023 | Tepezza |
| Takeda Pharmaceuticals U.S.A., INC. | $104.15 | 2022-2025 | Entyvio, Glassia |
| Adma Biomanufacturing LLC | $102.20 | 2023-2024 | |
| Astrazeneca Pharmaceuticals Lp | $96.70 | 2022-2024 | Saphnelo |
| Glaxosmithkline, LLC. | $82.10 | 2022-2025 | Nucala |
| Abbvie INC. | $64.07 | 2024-2025 | |
| Biogen, INC. | $60.00 | 2023 | Tysabri |
| Kyowa Kirin, INC. | $45.96 | 2023-2024 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.11 | 2024-2025 | Spevigo |
| Daiichi Sankyo INC. | $37.06 | 2022-2024 | Injectafer |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $33.53 | 2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $31.43 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $27.90 | 2023 | Truxima |
| Genentech USA, INC. | $25.33 | 2024 | Xolair |
| Argenx US, INC. | $25.17 | 2024 | Vyvgart Hytrulo |
| Pfizer INC. | $23.61 | 2025 | |
| Organon LLC | $18.05 | 2022 | |
| Novo Nordisk INC | $16.53 | 2022 | |
| Eisai INC. | $14.25 | 2023 | |
| Amag Pharmaceuticals, INC. | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.